Literature DB >> 17241664

Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.

Melissa M Damschroder1, Lusiana Widjaja, Parkash S Gill, Valery Krasnoperov, Weidong Jiang, William F Dall'Acqua, Herren Wu.   

Abstract

We report here the humanization of two mouse monoclonal antibodies (mAb) using framework shuffling of human germline genes. mAbs EA2 and 47 were raised against the human receptor tyrosine kinase EphA2 and EphB4, respectively, which exhibit increased expression levels in many cancer cell lines. One- and two-step strategies were carried out, in which the light and heavy chains of each parental mAb were simultaneously or sequentially humanized. We characterized in detail these newly humanized antibodies in terms of binding affinity to their respective antigen, functional activity, thermostability, electric charge and expression yields. Three previously described framework shuffled, humanized versions of another mouse anti-human EphA2 antibody (mAb B233) were similarly characterized. We show that several of these parameters were either maintained or improved in all humanized molecules when compared with their respective chimaeric counterpart. Therefore, this humanization approach is generally applicable to non-human IgGs and allows for the specific selection of antibodies and antibody fragments exhibiting favorable functional, biochemical and biophysical properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17241664     DOI: 10.1016/j.molimm.2006.12.019

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  16 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.

Authors:  Kota Iwahori; Sunitha Kakarla; Mireya P Velasquez; Feng Yu; Zongzhen Yi; Claudia Gerken; Xiao-Tong Song; Stephen Gottschalk
Journal:  Mol Ther       Date:  2014-08-21       Impact factor: 11.454

Review 3.  CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Authors:  Brooke L Prinzing; Stephen M Gottschalk; Giedre Krenciute
Journal:  Expert Rev Anticancer Ther       Date:  2018-03-16       Impact factor: 4.512

4.  Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70).

Authors:  Kirstin A Zettlitz; Julia Seitter; Dafne Müller; Roland E Kontermann
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

5.  T cells redirected to EphA2 for the immunotherapy of glioblastoma.

Authors:  Kevin K H Chow; Swati Naik; Sunitha Kakarla; Vita S Brawley; Donald R Shaffer; Zhongzhen Yi; Nino Rainusso; Meng-Fen Wu; Hao Liu; Yvonne Kew; Robert G Grossman; Suzanne Powell; Dean Lee; Nabil Ahmed; Stephen Gottschalk
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

6.  Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer.

Authors:  Ning Li; Shaohui Liu; Mingjiao Sun; Wei Chen; Xiaogang Xu; Zhu Zeng; Yemin Tang; Yongquan Dong; Alex H Chang; Qiong Zhao
Journal:  Transl Oncol       Date:  2017-11-10       Impact factor: 4.243

7.  T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies.

Authors:  Mireya Paulina Velasquez; David Torres; Kota Iwahori; Sunitha Kakarla; Caroline Arber; Tania Rodriguez-Cruz; Arpad Szoor; Challice L Bonifant; Claudia Gerken; Laurence J N Cooper; Xiao-Tong Song; Stephen Gottschalk
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

8.  Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.

Authors:  Zhongzhen Yi; Brooke L Prinzing; Felicia Cao; Stephen Gottschalk; Giedre Krenciute
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-02       Impact factor: 6.698

9.  Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy.

Authors:  Reena Varkey; Qun Du; Jodi L Karnell; Xiaodong Xiao; Kerry A Casey; Rob Woods; Kim Rosenthal; Susan Wilson; William F Dall'Acqua; Herren Wu; Ronald Herbst; Rachel Ettinger; Melissa Damschroder
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

10.  Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours.

Authors:  Kenneth Hsu; Shiloh Middlemiss; Federica Saletta; Stephen Gottschalk; Geoffrey B McCowage; Belinda Kramer
Journal:  Cancer Gene Ther       Date:  2020-09-01       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.